Core Points - Shanghai Zhijiang Biological Technology Co., Ltd. has recently obtained a Class III medical device registration certificate for one of its products, enhancing its product offerings and overall competitiveness in the market [1] Group 1: Medical Device Registration - The company has received a registration certificate for a product that utilizes mature fluorescence PCR technology and lyophilization processes, aimed at providing a precise and convenient testing tool for clinical use [1] Group 2: Impact on the Company - The approval of the new product enriches the company's existing product range and strengthens its comprehensive competitiveness in the industry [1] Group 3: Share Buyback Announcement - On October 15, 2025, the company approved a share buyback plan, intending to repurchase shares using its own funds and a special loan for stock buybacks, with a total amount between RMB 60 million and RMB 120 million [7] - The buyback price is set at a maximum of RMB 37.99 per share, with a buyback period of 12 months from the board's approval date [7] - As of October 31, 2025, the company had not yet implemented the share buyback, but on November 3, 2025, it repurchased 92,000 shares at a total cost of RMB 2.0881 million, representing 0.05% of the total share capital [8]